STOCKHOLM, May 9, 2025 — 

FIRST QUARTER (JANUARY – MARCH 2025)

• Order intake reached SEK 409.6 M (238.5)
• Net sales totaled SEK 331.7 M (257.2)
• Operating profit was SEK 74.8 M (45.8)
• Profit after tax amounted to SEK 56.8 M (36.7)
• Earnings per share, both before and after dilution, were SEK 1.66 (1.07)
• Cash flow from operating activities was SEK 146.8 M (167.3)
• The order backlog at the end of the period was SEK 1,734.4 M (1,848.0).

SIGNIFICANT EVENTS DURING THE FIRST QUARTER

• The number of radiation therapy centers globally using RayStation now exceeds 1,100.
• RaySearch secured its initial order for DrugLog, stemming from Medim’s successful bid in a tender from Poland’s largest pediatric hospital, The Children’s Memorial Health Institute.
• Heyou Hospital, a Chinese carbon ion center, has placed an order for RayStation. Valued at RMB 51M (approximately SEK 77 M), this is the third-largest order in RaySearch’s history. RMB 18 M (approximately SEK 26 M) was recognized as revenue during the first quarter.
• In March 2025, Johan Löf, RaySearch’s CEO and a board member, sold 2,000,000 B-shares in RaySearch Laboratories AB (publ), representing 5.8 percent of the share capital. The sale involved converting 2,000,000 A-shares into B-shares. Following the conversion, RaySearch’s total number of votes is 85,177,548, and the total number of registered shares is 34,282,773, comprising 5,654,975 A-shares and 28,627,798 B-shares. After the sale, Johan Löf controls 40.5 percent of the total votes and 10.2 percent of the share capital.

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

• In May 2025, the release of RayStation v2025, the latest version of the company’s innovative treatment planning system, was announced.
• In May 2025, it was announced that The Royal Marsden NHS Foundation Trust in the UK has begun treating patients using a new, advanced workflow facilitated by the adaptive replanning module included in the newest RayStation version.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Johan Löf, CEO                      Tel: +46 8 510 530 00, e-mail:

Nina Grönberg, CFO              Tel: +46 8 510 530 00, e-mail:

RaySearch Laboratories AB (publ) is obligated to disclose the information provided in this year-end report under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was released for publication on May 9, 2025, at 7:45 a.m.

WEBCAST

Johan Löf, CEO, and Nina Grönberg, CFO, will present RaySearch’s first quarter 2025 interim report in an English-language webcast on Friday, May 9, 2025, from 10:00-10:30 a.m. CEST.

Link to webcast:

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company focused on developing innovative software solutions that improve cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. RayIntelligence® and RayCommand®* are the most recent additions to the RaySearch product line. RayIntelligence is an oncology analytics system (OAS) that allows cancer clinics to gather, structure, and analyze data. RayCommand, a treatment control system (TCS), is designed to connect the treatment machine with the treatment planning and oncology information systems.

RaySearch software has been sold to more than 1,100 clinics across 47 countries. The company was established in 2000 as a spin-off from the Karolinska Institute in Stockholm, and its shares have been listed on Nasdaq Stockholm since 2003. Further details are available at .

* Subject to regulatory clearance in some markets.

This information was brought to you by Cision

The following files are available for download:

SOURCE RaySearch Laboratories

“`